Your browser doesn't support javascript.
loading
Antibiotic misuse: How to evaluate the costs?
Silva, M L; Cargnello, C; Aulois-Griot, M; Dumartin, C.
Afiliação
  • Silva ML; Unité Inserm 1219, UFR sciences pharmaceutiques- laboratoire de droit et économie pharmaceutiques, université de Bordeaux, 146, rue Léo-Saignat, case postale 81, 33076 Bordeaux, France. Electronic address: maria-laura.silva@u-bordeaux.fr.
  • Cargnello C; Unité Inserm 1219, UFR sciences pharmaceutiques- laboratoire de droit et économie pharmaceutiques, université de Bordeaux, 146, rue Léo-Saignat, case postale 81, 33076 Bordeaux, France.
  • Aulois-Griot M; Unité Inserm 1219, UFR sciences pharmaceutiques- laboratoire de droit et économie pharmaceutiques, université de Bordeaux, 146, rue Léo-Saignat, case postale 81, 33076 Bordeaux, France.
  • Dumartin C; Unité Inserm 1219, UFR sciences pharmaceutiques- laboratoire de droit et économie pharmaceutiques, université de Bordeaux, 146, rue Léo-Saignat, case postale 81, 33076 Bordeaux, France; CHU Bordeaux, CPIAS Nouvelle Aquitaine, hôpital Pellegrin - bâtiment Le Tondu, 33076 Bordeaux, France.
Med Mal Infect ; 49(7): 485-494, 2019 Oct.
Article em En | MEDLINE | ID: mdl-30954321
ABSTRACT

OBJECTIVE:

Few studies have assessed the costs associated with the misuse of antibiotics in hospitals in France, despite the value of health economic data to inform antibiotic stewardship activities. We aimed to identify the methodological tools used to assess the cost of antibiotic misuse in hospitals.

METHODS:

We performed a literature review using the major electronic medical databases. An index of relevance was developed to assess the intrinsic quality of selected articles.

RESULTS:

Four hundred and three articles were retrieved, but 35 were selected for analysis. Most studies investigated the inadequate choice of the antibiotic molecule (n=17), the incorrect treatment duration (n=9), and the administration of an inappropriate dosage (n=7). Only three studies were medical/economic evaluations of specific interventions, such as prescription control by pharmacists or the implementation of a new diagnostic test. Considering our aim, the relevance of the studies was limited few had defined the economic assessment as the primary objective or had detailed the method for calculating costs. Nevertheless, the misuse evaluation was usually better described.

CONCLUSIONS:

Despite these limits, key factors for measuring antibiotic misuse (i.e., molecule choice, dosage) in relation to the costs (i.e., over/under prescription, hospital stay, staff remuneration) might serve as the basis for the development of a reference methodology to value the costs of misuse. The application of this methodology on identified situations of antibiotic misuse would help hospital decision-makers to justify resource allocation for implementing antimicrobial stewardship activities.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custos e Análise de Custo / Economia Hospitalar / Uso Indevido de Medicamentos / Antibacterianos Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Med Mal Infect Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Custos e Análise de Custo / Economia Hospitalar / Uso Indevido de Medicamentos / Antibacterianos Tipo de estudo: Health_economic_evaluation / Prognostic_studies / Systematic_reviews Limite: Humans País/Região como assunto: Europa Idioma: En Revista: Med Mal Infect Ano de publicação: 2019 Tipo de documento: Article